Vikesh Singh, MD, MSc 

Early Diagnosis

Video content above is prompted by the following:

Can you describe the importance of early diagnosis and treatment of FCS?

Why are the signs and symptoms of FCS often misunderstood, leading to delayed diagnosis? How often does delayed diagnosis occur?

Videos

Early diagnosis and treatment of Familial Chylomicronemia Syndrome (FCS) are crucial to prevent severe complications such as pancreatitis and to improve quality of life. FCS symptoms, including abdominal pain and fatigue, are often misattributed to more common conditions, leading to diagnostic delays. This misinterpretation is exacerbated by the rarity of FCS and lack of awareness among healthcare providers. Delayed diagnosis is common, with many patients experiencing symptoms for years before receiving an accurate diagnosis, underscoring the need for increased education and awareness in the medical community.

Panelists discuss how clinically -diagnosed (or functional) Familial Chylomicronemia Syndrome (FCS), involving a bi-allelic genetic defect, differs in diagnostic approach from classical FCS, emphasizing the challenges of diagnosing without genetic confirmation.

Genetic Testing

What is clinically-diagnosed (or functional) FCS (with a bi-allelic genetic defect), and how does the approach to its diagnosis differ from classical FCS? 

Clinically-diagnosed familial chylomicronemia syndrome (FCS) with a bi-allelic genetic defect is characterized by severe hypertriglyceridemia due to impaired lipoprotein lipase activity. Unlike classical FCS, which is confirmed through genetic testing, functional FCS diagnosis relies on clinical presentation and exclusion of secondary causes. The diagnostic approach for functional FCS involves assessing triglyceride levels, ruling out other conditions, and considering family history. Genetic testing may not always be available or conclusive, necessitating a clinical diagnosis based on symptomatology and biochemical findings.

Metabolic Disorders and Delayed Diagnosis

What are the potential cardiovascular and metabolic consequences associated with a delayed diagnosis and treatment of FCS? 

What are the possible long-term consequences and health risks?

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels, leading to recurrent pancreatitis and other complications. Delayed diagnosis and treatment can exacerbate cardiovascular and metabolic consequences, including increased risk of atherosclerosis, cardiovascular disease, and metabolic syndrome. Long-term health risks involve persistent hypertriglyceridemia, which can cause chronic pancreatitis, diabetes, and liver disease. Early intervention is crucial to mitigate these risks, improve patient outcomes, and enhance quality of life by managing triglyceride levels and preventing severe complications.

Panelists discuss the potential cardiovascular and metabolic consequences of a delayed diagnosis and treatment of Familial Chylomicronemia Syndrome (FCS), emphasizing the long-term health risks, including an increased risk of acute pancreatitis, cardiovascular disease, and metabolic complications.

Pathophysiology of FCS

What role does do genetic mutations, such as mutation of the

 gene, play in the pathophysiology of FCS? 

Genetic mutations, particularly in the LPL gene, are central to the pathophysiology of Familial Chylomicronemia Syndrome (FCS). The LPL gene encodes lipoprotein lipase, an enzyme crucial for the hydrolysis of triglycerides in chylomicrons. Mutations in this gene lead to a deficiency or dysfunction of lipoprotein lipase, resulting in impaired triglyceride metabolism. This impairment causes the accumulation of chylomicrons in the bloodstream, leading to severe hypertriglyceridemia and associated clinical manifestations. Understanding these genetic mutations is essential for diagnosing and developing targeted therapies for FCS.

Panelists discuss how genetic mutations, such as mutations in the LPL gene, play a critical role in the pathophysiology of Familial Chylomicronemia Syndrome (FCS) by impairing triglyceride metabolism and increasing the risk of severe hypertriglyceridemia.

Vikesh Singh, MD, MSc

Articles